F H Messerli

Summary

Publications

  1. ncbi request reprint beta-Blockers in hypertension: is carvedilol different?
    Franz H Messerli
    Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
    Am J Cardiol 93:7B-12B. 2004
  2. ncbi request reprint The president and the pheochromocytoma
    Franz H Messerli
    St Luke s Roosevelt Hospital Center, New York, New York, USA
    Am J Cardiol 99:1325-9. 2007
  3. ncbi request reprint b-Blockers and hypertension: A therapeutic reappraisal
    Franz H Messerli
    New York, NY 10019, USA
    Postgrad Med 118:26-33. 2005
  4. ncbi request reprint Evolution of calcium antagonists: past, present, and future
    Franz H Messerli
    Section on Hypertensive Diseases, Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
    Clin Cardiol 26:II12-6. 2003
  5. ncbi request reprint If only cardiologists did properly measure blood pressure. Blood pressure recordings in daily practice and clinical trials
    Franz H Messerli
    Ochsner Clinic Foundation, New Orleans, Louisiana, USA
    J Am Coll Cardiol 40:2201-3. 2002
  6. doi request reprint The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?
    Franz H Messerli
    Division of Cardiology, St Luke s Roosevelt Hospital Center, Columbia University, College of Physicians and Surgeons, New York, New York 10019, USA
    J Am Coll Cardiol 54:1827-34. 2009
  7. ncbi request reprint Crumbling of left ventricular hypertrophy as a surrogate end point (the Losartan for Intervention for Endpoint Reduction in Hypertension [LIFE] Study)
    Franz H Messerli
    Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Am J Cardiol 90:1133-4. 2002
  8. ncbi request reprint Vasodilatory edema: a common side effect of antihypertensive therapy
    Franz H Messerli
    Department of Internal Medicine, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Curr Cardiol Rep 4:479-82. 2002
  9. ncbi request reprint Q: Is an ACE inhibitor plus an ARB more effective than either drug alone?
    Franz H Messerli
    Division of Cardiology, St Luke s Roosevelt Hospital Center, 1000 10th Avenue, New York, NY 10019, USA
    Cleve Clin J Med 76:693-6. 2009
  10. ncbi request reprint ALLHAT, or the soft science of the secondary end point
    Franz H Messerli
    Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
    Ann Intern Med 139:777-80. 2003

Collaborators

Detail Information

Publications102 found, 100 shown here

  1. ncbi request reprint beta-Blockers in hypertension: is carvedilol different?
    Franz H Messerli
    Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
    Am J Cardiol 93:7B-12B. 2004
    ....
  2. ncbi request reprint The president and the pheochromocytoma
    Franz H Messerli
    St Luke s Roosevelt Hospital Center, New York, New York, USA
    Am J Cardiol 99:1325-9. 2007
    ..In conclusion, most likely, the pheochromocytoma was the underlying cause of this erratic blood pressure pattern and may have worsened the course of the president's ischemic cardiomyopathy...
  3. ncbi request reprint b-Blockers and hypertension: A therapeutic reappraisal
    Franz H Messerli
    New York, NY 10019, USA
    Postgrad Med 118:26-33. 2005
    ..Here, the authors consider the extended debate on this topic and discuss the mechanisms of action for traditional and newer b-blockers and their role in hypertension management...
  4. ncbi request reprint Evolution of calcium antagonists: past, present, and future
    Franz H Messerli
    Section on Hypertensive Diseases, Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
    Clin Cardiol 26:II12-6. 2003
    ..Newer calcium antagonists demonstrate antihypertensive efficacy similar to that of their predecessors but appear to have a reduced propensity to cause edema...
  5. ncbi request reprint If only cardiologists did properly measure blood pressure. Blood pressure recordings in daily practice and clinical trials
    Franz H Messerli
    Ochsner Clinic Foundation, New Orleans, Louisiana, USA
    J Am Coll Cardiol 40:2201-3. 2002
    ..Whether measured in office or clinical trials, BP is an important clinical tool that should be treasured by practitioners and clinical investigators alike...
  6. doi request reprint The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?
    Franz H Messerli
    Division of Cardiology, St Luke s Roosevelt Hospital Center, Columbia University, College of Physicians and Surgeons, New York, New York 10019, USA
    J Am Coll Cardiol 54:1827-34. 2009
    ..However, these concerns should not deter physicians from pursuing a more aggressive control of hypertension, because currently blood pressure is brought to recommended target levels in only approximately one-third of patients...
  7. ncbi request reprint Crumbling of left ventricular hypertrophy as a surrogate end point (the Losartan for Intervention for Endpoint Reduction in Hypertension [LIFE] Study)
    Franz H Messerli
    Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Am J Cardiol 90:1133-4. 2002
  8. ncbi request reprint Vasodilatory edema: a common side effect of antihypertensive therapy
    Franz H Messerli
    Department of Internal Medicine, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Curr Cardiol Rep 4:479-82. 2002
    ..Thus, low-dose combination therapy (of a dihydropyridine calcium antagonist with either an ACE inhibitor or an ARB) may be preferred over high-dose monotherapy...
  9. ncbi request reprint Q: Is an ACE inhibitor plus an ARB more effective than either drug alone?
    Franz H Messerli
    Division of Cardiology, St Luke s Roosevelt Hospital Center, 1000 10th Avenue, New York, NY 10019, USA
    Cleve Clin J Med 76:693-6. 2009
    ..No. Dual renin-angiotensin system blockade has never been shown to reduce the rates of morbidity or death from any cause...
  10. ncbi request reprint ALLHAT, or the soft science of the secondary end point
    Franz H Messerli
    Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
    Ann Intern Med 139:777-80. 2003
    ....
  11. ncbi request reprint Do thiazide diuretics confer specific protection against strokes?
    Franz H Messerli
    Department of Internal Medicine, Section on Hypertensive Diseases, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Arch Intern Med 163:2557-60. 2003
    ....
  12. ncbi request reprint Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial
    Franz H Messerli
    St Luke s Roosevelt Hospital Center, New York, NY 10019, USA
    J Clin Hypertens (Greenwich) 8:571-81; quiz 582-3. 2006
    ..Concomitant administration of amlodipine and atorvastatin is an effective and well tolerated treatment for coexisting hypertension and dyslipidemia...
  13. ncbi request reprint Body weight changes with beta-blocker use: results from GEMINI
    Franz H Messerli
    St Luke s Roosevelt Hospital Center, New York City, NY 10019, USA
    Am J Med 120:610-5. 2007
    ....
  14. ncbi request reprint Essential hypertension
    Franz H Messerli
    Division of Cardiology, St Luke s Roosevelt Hospital Center, Columbia University, College of Physicians and Surgeons, New York, NY 10019, USA
    Lancet 370:591-603. 2007
    ..Despite the availability of effective and safe antihypertensive drugs, hypertension and its concomitant risk factors remain uncontrolled in most patients...
  15. ncbi request reprint Therapeutic controversies in hypertension
    Franz H Messerli
    St Lukes Roosevelt Hospital Center, New York, NY 10019, USA
    Semin Nephrol 25:227-35. 2005
    ..The long-term safety of antihypertensive therapy is documented poorly because most trials only last 4 to 6 years. Despite these drawbacks and concerns, the benefits of antihypertensive therapy clearly outweigh its potential risk...
  16. ncbi request reprint When premature is not premature--the ASCOT study
    Franz H Messerli
    Department of Cardiology, St Luke s Roosevelt Hospital Center, Columbia University, 1000, Tenth Avenue, Suite 3B 30, New York 10019, NY, USA
    Eur Heart J 26:1822-3. 2005
  17. ncbi request reprint Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis
    Franz H Messerli
    Division of Cardiology, St Luke s Roosevelt Hospital, New York, New York, USA
    Am J Cardiol 101:319-25. 2008
    ..51, p=0.22). In conclusion, statin therapy effectively decreases CV morbidity and mortality to the same extent in hypertensive and nonhypertensive patients...
  18. doi request reprint Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension
    Franz H Messerli
    Division of Cardiology, St Luke s Roosevelt Hospital, Columbia University College of Physicians and Surgeons, 1000 10th Ave, Suite 3B 30, New York, NY 10019, USA
    Circulation 117:2706-15; discussion 2715. 2008
  19. ncbi request reprint Safety of calcium antagonists: more ACTION
    Franz H Messerli
    St Lukes Roosevelt Hospital Corporation, New York City, New York, USA
    Am J Med 118:1418-20. 2005
  20. ncbi request reprint Calcium antagonists in hypertension: from hemodynamics to outcomes
    Franz H Messerli
    Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
    Am J Hypertens 15:94S-97S. 2002
    ..These micro- and macrovascular features make lercanidipine an attractive new member in the arsenal of the powerful dihydropyridine calcium antagonists...
  21. ncbi request reprint Blood pressure control in stroke patients: what should the consulting neurologist advise?
    Franz H Messerli
    Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA 70121, USA
    Neurology 59:23-5. 2002
  22. ncbi request reprint High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal?
    E Grossman
    Ochsner Clinic, 1514 Jefferson Hwy, New Orleans, LA 70121
    Arch Intern Med 160:2447-52. 2000
    ..To analyze the available data to assess the benefits of antihypertensive therapy in hypertensive patients with diabetes mellitus...
  23. ncbi request reprint Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review
    F H Messerli
    Department of Internal Medicine, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, LA 70121, USA
    JAMA 279:1903-7. 1998
    ..To assess antihypertensive efficacy of beta-blockers and their effects on cardiovascular morbidity and mortality and all-cause morbidity compared with diuretics in elderly patients with hypertension...
  24. ncbi request reprint Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
    Franz H Messerli
    Division of Cardiology, St Luke s Roosevelt Hospital, New York, New York 10019, USA
    Ann Intern Med 144:884-93. 2006
    ..Because coronary perfusion occurs mainly during diastole, patients with coronary artery disease (CAD) could be at increased risk for coronary events if diastolic pressure falls below critical levels...
  25. ncbi request reprint Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients
    F H Messerli
    Department of Internal Medicine, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana, USA
    J Hypertens 19:977-82. 2001
    ..To analyse effects of a heart rate-lowering calcium antagonist in hypertensive post-myocardial infarction patients...
  26. ncbi request reprint Doxazosin and congestive heart failure
    F H Messerli
    Department of Internal Medicine, Section on Hypertensive Diseases, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA
    J Am Coll Cardiol 38:1295-6. 2001
    ..Therefore, until ironclad safety data are provided, doxazosin, and probably all alpha-blockers, should no longer be used as first-line antihypertensive therapy...
  27. ncbi request reprint Carcinogenicity of antihypertensive therapy
    Ehud Grossman
    Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Curr Hypertens Rep 4:195-201. 2002
    ..With regard to other antihypertensive drug classes, we suggest continuing the management of hypertension according to current treatment guidelines with little fear of any substantial cancer risk...
  28. ncbi request reprint Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting
    Franz H Messerli
    Division of Research, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
    Am J Hypertens 15:550-6. 2002
    ..This large practice-based clinical trial assessed the efficacy and tolerability of fixed-dose combination therapy with amlodipine/benazepril, compared with amlodipine monotherapy, in patients with mild-to-moderate hypertension...
  29. ncbi request reprint Antihypertensive therapy in diabetic hypertensive patients
    F H Messerli
    Department of Internal Medicine, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA
    Am J Hypertens 14:12S-16S. 2001
    ..Combination of more than one drug is frequently required to control BP and may be more beneficial than monotherapy...
  30. doi request reprint Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy
    Sripal Bangalore
    Division of Cardiovascular Medicine, St Luke s Roosevelt Hospital Center, New York, NY 10025, USA
    Am Heart J 156:241-7. 2008
    ..The purpose of the study was to compare a beta-blocker-based strategy with a heart rate-lowering calcium antagonists-based strategy in patients with prior MI...
  31. ncbi request reprint Combination therapy and target organ protection in hypertension and diabetes mellitus
    F H Messerli
    Department of Internal Medicine, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA
    Am J Hypertens 10:198S-201S. 1997
    ..The combination of a heart rate lowering calcium antagonist, particularly verapamil, with an ACE inhibitor offers some potential to either prevent or reverse target organ disease associated with hypertension and diabetes...
  32. ncbi request reprint Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI
    V Fonseca
    Tulane University, New Orleans, LA 70112, USA
    Diabet Med 24:759-63. 2007
    ..To determine whether the beneficial effects of carvedilol on insulin resistance (IR) are affected by the concomitant use of insulin sensitizers [thiazolidinediones (TZDs) and metformin]...
  33. ncbi request reprint Combinations in the treatment of hypertension: ACE inhibitors and calcium antagonists
    F H Messerli
    Department of Internal Medicine, Section on Hypertensive Diseases, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana, USA
    Am J Hypertens 12:86S-90S. 1999
    ..However, their use together in left ventricular hypertrophy and in patients with coronary heart disease, although promising, must be proved through carefully designed, prospective, randomized trials...
  34. ncbi request reprint Obesity paradox in patients with hypertension and coronary artery disease
    Seth Uretsky
    Division of Cardiology, St Luke s Roosevelt Hospital, New York, NY, USA
    Am J Med 120:863-70. 2007
    ..However, whether this phenomenon exists in patients with hypertension and coronary artery disease is not known...
  35. ncbi request reprint Beta-blockers and diuretics: to use or not to use
    F H Messerli
    Department of Internal Medicine, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA
    Am J Hypertens 12:157S-163S. 1999
    ..Sweeping recommendations for the use of beta-blockers and diuretics as preferred therapeutic strategies are inappropriate and a more sophisticated drug therapy regimen is often needed...
  36. ncbi request reprint Hemodynamic effects of celiprolol in essential hypertension
    E D Frohlich
    Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121
    Am J Cardiol 68:509-14. 1991
    ..These effects may be explained by celiprolol's cardiac beta-1 receptor inhibitory and peripheral beta-2 receptor agonistic effects...
  37. ncbi request reprint A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus
    Sripal Bangalore
    Department of Medicine, Division of Cardiology, St Luke s Roosevelt Hospital and Columbia University College of Physicians and Surgeons, New York, NY, USA
    Am J Cardiol 100:1254-62. 2007
    ..This risk was greater in patients with higher baseline body mass indexes and higher baseline fasting glucose levels and in studies in which beta blockers were less efficacious antihypertensive agents compared with other treatments...
  38. ncbi request reprint Calcium antagonists and beta-blockers: impact on cardiovascular and cerebrovascular events
    Franz H Messerli
    St Luke s Roosevelt Hospital Center, New York, New York 10019, USA
    Clin Cornerstone 6:18-27. 2004
    ..This article reviews the data on risk reduction involving the beta-blockers and calcium antagonists, as well as other antihypertensive classes that have been shown to reduce the risk of cerebrovascular and cardiovascular disease...
  39. doi request reprint The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point
    Franz H Messerli
    Division of Cardiology, St Luke s Roosevelt Hospital Center, Columbia University College of Medicine and Physicians, New York, NY 10019, USA
    J Am Coll Cardiol 53:468-70. 2009
    ..Unless data emerge to the contrary, dual RAS blockade should no longer be used in clinical practice...
  40. ncbi request reprint Feasibility of treating prehypertension with an angiotensin-receptor blocker
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, Ann Arbor, MI 48106, USA
    N Engl J Med 354:1685-97. 2006
    ..Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk. We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension...
  41. ncbi request reprint Fixed-dose combinations improve medication compliance: a meta-analysis
    Sripal Bangalore
    Department of Medicine, Division of Cardiology, St Luke s Roosevelt Hospital and Columbia University, New York, NY 10025, USA
    Am J Med 120:713-9. 2007
    ..However the data on comparison of fixed-dose combination with free-drug regimen to improve patient's medication compliance is limited...
  42. doi request reprint Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis
    Sripal Bangalore
    Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, St Luke s Roosevelt Hospital Center, 1000 Tenth Avenue, Suite 3B 30, New York, NY 10025, USA
    Eur Heart J 30:1395-401. 2009
    ....
  43. ncbi request reprint Hypertension in the elderly: a compelling contraindication for beta-blockers?
    S Bangalore
    Department of Medicine, Division of Cardiology, St Luke s Roosevelt Hospital and Columbia University, New York, NY 10019, USA
    J Hum Hypertens 21:259-60. 2007
  44. ncbi request reprint Cardioprotection with beta-blockers: myths, facts and Pascal's wager
    F H Messerli
    Division of Cardiology, St Luke s and Roosevelt Hospitals, Columbia University College of Physicians and Surgeons, New York, NY 10019, USA
    J Intern Med 266:232-41. 2009
    ..Thus, recent evidence argues against universal cardioprotective properties of beta-blockers but attest to their usefulness for specific cardiovascular indications...
  45. ncbi request reprint A review of stroke in patients with hypertension and coronary artery disease: Focus on calcium channel blockers
    S Bangalore
    Division of Cardiology, Department of Medicine, St Luke s Roosevelt Hospital and Columbia University, New York, NY 10025, USA
    Int J Clin Pract 60:1281-6. 2006
    ..Moreover, the incidence of stroke is significantly related to baseline BP, which may be an important factor to consider when deciding on treatment strategies in high-risk patients with CAD...
  46. ncbi request reprint Angiotensin converting enzyme inhibitors. Disparities in the mechanism of their antihypertensive effect
    G E Garavaglia
    Department of Internal Medicine, Ochsner Clinic, New Orleans, LA 70121
    Am J Hypertens 1:214S-216S. 1988
    ..These findings suggest that systemic and renal hemodynamic effects may be drug specific and not uniform for all ACE inhibitors...
  47. ncbi request reprint Compliance and fixed-dose combination therapy
    Sripal Bangalore
    Hypertension Program, Division of Cardiology, Columbia University College of Physicians and Surgeons, St Luke s Roosevelt Hospital Center, 1000 Tenth Avenue, Suite 3B 30, New York, NY 10025, USA
    Curr Hypertens Rep 9:184-9. 2007
    ..Fixed-dose combinations should be used routinely for the management of hypertension and should also be considered when initiating therapy for patients with newly diagnosed hypertension...
  48. doi request reprint Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension
    Sripal Bangalore
    Department of Medicine, Division of Cardiology, St Luke s Roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York, New York 10019, USA
    J Am Coll Cardiol 52:1482-9. 2008
    ..The purpose of this study was to evaluate the role of heart rate reduction with beta-blockers on the risk of cardiovascular events in patients with hypertension...
  49. ncbi request reprint Cardiac effects of combination therapy
    F H Messerli
    Department of Internal Medicine, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA
    Am J Hypertens 10:146S-152S. 1997
    ..Thus, combination therapy should primarily be used for lowering arterial pressure and only secondarily to possibly improve concomitant pathophysiologic conditions associated with hypertensive heart disease...
  50. ncbi request reprint Desperate diseases, desperate measures: tackling malignant hypertension in the 1950s
    H O Ventura
    Department of Cardiology, and the Section of Hypertension, Department of Medicine, Ochsner Medical Institutions, New Orleans, LA 70121, USA
    Am Heart J 142:197-203. 2001
    ..As we enter the new millennium, it is critical to examine the efforts that have led to our ability to treat this once incurable disease...
  51. ncbi request reprint What, if anything, is controversial about calcium antagonists?
    F H Messerli
    Department of Internal Medicine, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA
    Am J Hypertens 9:177S-181S. 1996
    ....
  52. ncbi request reprint Cardiovascular adaptation to cyclosporine-induced hypertension
    H O Ventura
    Department of Internal Medicine, Ochsner Medical Institutions, New Orleans, LA 70112
    J Hum Hypertens 8:233-7. 1994
    ..The cardiac adaptation to cyclosporine-induced hypertension has more severe concentric left ventricular hypertrophy and impaired left ventricular systolic performance.(ABSTRACT TRUNCATED AT 250 WORDS)..
  53. ncbi request reprint Efficacy and safety of angiotensin II receptor blockers in elderly patients with mild to moderate hypertension
    C E Okereke
    Department of Internal Medicine, Section on Hypertensive Diseases, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, LA, USA
    Am J Geriatr Cardiol 10:42-9. 2001
    ..Combination therapy with angiotensin receptor blockers and hydrochlorothiazide was additive, without any significant effect on the safety profile...
  54. ncbi request reprint Hypertension and sudden cardiac death
    F H Messerli
    Department of Internal Medicine, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA
    Am J Hypertens 12:181S-188S. 1999
    ....
  55. ncbi request reprint Beta-blockers: no longer an option for uncomplicated hypertension
    Sripal Bangalore
    Hypertension Program, Division of Cardiology, St Luke s Roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York, NY 10019, USA
    Curr Cardiol Rep 9:441-6. 2007
    ..This article reviews the data available from clinical trials and argues that beta-blockers are less efficacious than other currently available antihypertensive agents for patients with uncomplicated hypertension...
  56. ncbi request reprint Beta-blockers for primary prevention in hypertension: era bygone?
    Gurusher S Panjrath
    Department of Cardiology, St Lukes Roosevelt Hospital Center, Division of Cardiology, Columbia University, NY 10019, USA
    Prog Cardiovasc Dis 49:76-87. 2006
    ..Newer beta-blockers have additional properties which may be beneficial. Although, whether these additional benefits will help in primary prevention is not clear...
  57. ncbi request reprint beta-Blockers in hypertension-the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension
    Franz H Messerli
    Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA
    Am J Hypertens 16:870-3. 2003
    ....
  58. ncbi request reprint Eisenhower's billion-dollar heart attack--50 years later
    Franz H Messerli
    St Luke s Roosevelt Hospital Center, New York, USA
    N Engl J Med 353:1205-7. 2005
  59. ncbi request reprint A novel pathway for the management of hypertension for hospitalized patients
    Eyal Herzog
    Division of Cardiology, St Luke s Roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York City, New York 10025, USA
    Crit Pathw Cardiol 6:150-60. 2007
    ..Finally, the pathway provides a step by step recommendation for the management of in hospital HTN and of hypertensive emergencies...
  60. doi request reprint Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis
    Sripal Bangalore
    Department of Medicine, Division of Cardiology, St Luke s Roosevelt Hospital and Columbia University College of Physicians and Surgeons, New York, New York 10019, USA
    J Am Coll Cardiol 52:1062-72. 2008
    ..This study sought to evaluate the efficacy of beta-blockers (BBs) for primary prevention of heart failure (HF) in patients with hypertension...
  61. ncbi request reprint Cardiovascular protection using beta-blockers: a critical review of the evidence
    Sripal Bangalore
    St Luke s Roosevelt Hospital and Columbia University, New York, New York 10019, USA
    J Am Coll Cardiol 50:563-72. 2007
    ..However, beta-blockers remain very efficacious agents for the treatment of heart failure, certain types of arrhythmia, hypertropic obstructive cardiomyopathy, and in patients with prior myocardial infarction...
  62. doi request reprint When guidelines need guidance
    Franz H Messerli
    Division of Cardiology, St Luke s Roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Am J Med 121:742-3. 2008
  63. ncbi request reprint Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis
    Sripal Bangalore
    Division of Cardiology, Brigham and Women s Hospital, Boston, MA, USA
    Lancet 372:1962-76. 2008
    ..We aimed to critically review the evidence to assess the use of perioperative beta blockers in patients having non-cardiac surgery...
  64. ncbi request reprint The association of the Friesinger score and pulse pressure in an urban South Asian patient population: pulse pressure, an independent predictor of coronary artery disease
    Fahad Javed
    St Luke s Roosevelt Hospital Center, University Hospital of College of Physicians and Surgeons of Columbia University, New York, NY, USA
    J Am Soc Hypertens 4:142-7. 2010
    ..7 vs. 20.3; P = .1139). Our study demonstrates that pulse pressure, a well-established marker of vascular health, is a significant independent predictor of the severity of CAD as assessed by coronary angiography in South Asians...
  65. ncbi request reprint How useful are beta-blockers in cardiovascular disease?
    Sripal Bangalore
    Department of Medicine, Division of Cardiology, St Luke s Roosevelt Hospital, Columbia University, New York, New York 10019, USA
    Anadolu Kardiyol Derg 6:358-63. 2006
    ..However, this is applicable for hypertension and beta-blockers continue to be efficacious for other indications...
  66. ncbi request reprint Left ventricular geometry and survival in patients with normal left ventricular ejection fraction
    Richard V Milani
    Department of Cardiology Ochsner Clinic Foundation, New Orleans, Louisiana, USA
    Am J Cardiol 97:959-63. 2006
    ..Normalization of CR is associated with better survival, whereas transition to LV hypertrophy increases mortality...
  67. doi request reprint Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis
    Sripal Bangalore
    Department of Medicine, Division of Cardiology, St Luke s Roosevelt Hospital and Columbia University College of Physicians and Surgeons, New York, NY 10019, USA
    Am J Med 122:356-65. 2009
    ..Short-acting CCBs have an unfavorable hemodynamic profile. The role of long-acting CCBs in patients with coronary artery disease is unknown...
  68. ncbi request reprint Disparate effects of left ventricular geometry and obesity on mortality in patients with preserved left ventricular ejection fraction
    Carl J Lavie
    Department of Cardiology, Ochsner Medical Center, New Orleans, LA, USA
    Am J Cardiol 100:1460-4. 2007
    ....
  69. ncbi request reprint Left ventricular geometry and mortality in patients >70 years of age with normal ejection fraction
    Carl J Lavie
    Ochsner Medical Center, New Orleans, Louisiana, USA
    Am J Cardiol 98:1396-9. 2006
    ....
  70. ncbi request reprint Effects of losartan in hypertension without vascular disease
    Franz H Messerli
    Ann Intern Med 140:W29. 2004
  71. ncbi request reprint Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials
    Albert Fournier
    Hopital Sud, Amiens Cedex I, France
    J Am Coll Cardiol 43:1343-7. 2004
    ..Stroke is the most devastating consequence of hypertensive cardiovascular disease, and our hypothesis of cerebroprotection by AT2 receptor activation should be tested by a head-to-head comparison of an ARB with an ACE inhibitor...
  72. ncbi request reprint Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study
    George L Bakris
    Rush Medical University, 1700 W Van Buren St, Suite 470, Chicago, IL
    Hypertension 44:637-42. 2004
    ..Thus, a verapamil SR-based antihypertensive treatment strategy is an alternative to a beta-blocker-based strategy in adults with CAD and diabetes...
  73. ncbi request reprint Are calcium antagonists beneficial in diabetic patients with hypertension?
    Ehud Grossman
    Internal Medicine D and Hypertension Unit, The Chaim Sheba Medical Center, Tel Hashomer, Israel
    Am J Med 116:44-9. 2004
    ..We analyzed the available data to assess the effects of calcium antagonists in hypertensive patients with diabetes mellitus...
  74. doi request reprint Perioperative beta blockade
    Sripal Bangalore
    Lancet 372:1147-8; author reply 1148. 2008
  75. doi request reprint Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk
    Michael A Weber
    Hypertension 51:1465-7. 2008
  76. ncbi request reprint Reduction of stroke risk factors
    John B Kostis
    J Clin Hypertens (Greenwich) 9:49-56. 2007
    ..Also participating were Philip B. Gorelick, MD, MPH, Director, Center for Stroke Research, University of Illinois College of Medicine, Chicago, IL, and Franz H. Messerli, MD, St Luke's-Roosevelt Hospital Center, New York, NY...
  77. ncbi request reprint A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial
    Carl J Pepine
    Division of Cardiovascular Medicine, Department of Medicine, University of Florida College of Medicine, Gainesville 32610, USA
    JAMA 290:2805-16. 2003
    ..Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials...
  78. ncbi request reprint ALLHAT--all hit or all miss? Key questions still remain
    Franz H Messerli
    Am J Cardiol 92:280-1. 2003
  79. ncbi request reprint A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
    Arnfried U Klingbeil
    Department of Medicine IV, University of Erlangen Nurnberg, Nuremberg, Germany
    Am J Med 115:41-6. 2003
    ..Antihypertensive medications have different effects on left ventricular mass. We conducted a meta-analysis of double-blind trials that measured the effects of antihypertensive therapy on left ventricular mass...
  80. ncbi request reprint Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors
    Franz H Messerli
    JAMA 289:2067-8; author reply 2069-70. 2003
  81. ncbi request reprint The LIFE study: the straw that should break the camel's back
    Franz H Messerli
    Eur Heart J 24:487-9. 2003
  82. ncbi request reprint Losartan vs atenolol in prevention of stroke and cardiovascular disease
    Franz H Messerli
    JAMA 289:700-1; author reply 701. 2003
  83. ncbi request reprint Pedal edema--not all dihydropyridine calcium antagonists are created equal
    Franz H Messerli
    Am J Hypertens 15:1019-20. 2002
  84. ncbi request reprint Why beta-blockers are not cardioprotective in elderly patients with hypertension
    Ehud Grossman
    Internal Medicine D, The Chaim Sheba Medical Center, Tel Hashomer, 52621, Israel
    Curr Cardiol Rep 4:468-73. 2002
    ..Decreased beta-adrenergic responsiveness with age and comorbid conditions makes beta-blockers unattractive. Thus, they should not be considered appropriate for first-line therapy of uncomplicated hypertension in the geriatric population...
  85. ncbi request reprint Beta-blockers in the treatment of hypertension: new data, new directions
    Michael A Weber
    State University of New York, Downstate Medical College, 450 Clarkson Avenue, Brooklyn, NY 11023, USA
    J Clin Hypertens (Greenwich) 10:234-8. 2008
  86. ncbi request reprint Calcium antagonists
    Ehud Grossman
    Internal Medicine D and Hyperstension Unit, The Chaim Sheba Medical Center, Tel Hashomer, Israel
    Prog Cardiovasc Dis 47:34-57. 2004
    ..Thus, calcium antagonists may be safely used in the management of hypertension and angina pectoris...
  87. ncbi request reprint Effect of ramipril on the incidence of diabetes
    Sripal Bangalore
    N Engl J Med 356:522; author reply 523-4. 2007
  88. ncbi request reprint Treatment of elderly hypertensive patients with a delayed-release verapamil formulation in a community-based trial
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
    Am J Geriatr Cardiol 13:131-6. 2004
    ..CODAS verapamil was found to be efficacious and well tolerated among elderly hypertensive patients in this community trial...
  89. ncbi request reprint Amlodipine/atorvastatin for preventing heart disease
    Franz H Messerli
    Am Fam Physician 75:311; author reply 311-2. 2007
  90. ncbi request reprint Do we need yet another blocker of the renin-angiotensin system?
    Franz H Messerli
    J Am Coll Cardiol 49:1164-5. 2007
  91. ncbi request reprint Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST])
    Rhonda Cooper-DeHoff
    University of Florida College of Medicine, Gainesville, Florida, USA
    Am J Cardiol 98:890-4. 2006
    ....
  92. ncbi request reprint Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies
    Franz H Messerli
    Hypertension 48:359-61. 2006
  93. ncbi request reprint Long-term safety of antihypertensive therapy
    Ehud Grossman
    Internal Medicine D and Hypertension Unit, The Chaim Sheba Medical Center, Tel Hashomer, Israel
    Prog Cardiovasc Dis 49:16-25. 2006
    ..Despite the concern that has been raised regarding the long-term safety of some antihypertensive agents, it is clear that lowering BP is safe and beneficial...
  94. ncbi request reprint Blood pressure control and sildenafil--carrot stick or sword of Damocles?
    Siu Sun Yao
    Am J Cardiol 100:552-3. 2007
  95. ncbi request reprint Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials
    Ji Guang Wang
    Studies Coordinating Centre, Hypertension and Cardiovascular Rehabilitation Unit, Department of Cardiovascular Diseases, University of Leuven, Belgium
    Stroke 37:1933-40. 2006
    ..We reviewed the randomized controlled trials that evaluated the effects of an antihypertensive drug versus placebo or another antihypertensive agent of a different class on carotid intima-media thickness...
  96. ncbi request reprint The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotection
    Laurent Magy
    Division of Neurology, CHU Limoges, France
    Curr Pharm Des 11:3275-91. 2005
    ..The perspective of a renewal of therapeutical strategies to optimise the prevention of target organ damage and perhaps even some of the diseases of ageing, such as loss of cognitive function is emphasised...
  97. ncbi request reprint Masked hypertension and white-coat hypertension: therapeutic navigation between scylla and charybdis
    Franz H Messerli
    J Am Coll Cardiol 46:516-7. 2005
  98. ncbi request reprint Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial
    Jackson T Wright
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
    J Clin Hypertens (Greenwich) 9:842-9. 2007
    ..The use of carvedilol compared with metoprolol did not effect glycemic control...
  99. ncbi request reprint Characteristics of contemporary patients with hypertension and coronary artery disease
    Rhonda M Cooper-Dehoff
    Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida 32610 0277, USA
    Clin Cardiol 27:571-6. 2004
    ..This is particularly true for black and Hispanic patients who have been underrepresented in randomized CAD trials...
  100. ncbi request reprint Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Ill, USA
    JAMA 292:2227-36. 2004
    ..Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however, some components of the metabolic syndrome are worsened by some beta-blockers...
  101. pmc Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST
    Antonio Coca
    Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Stroke 39:343-8. 2008
    ..Accordingly, factors predicting stroke risk in hypertensive, clinically stable coronary artery disease patients were determined with data from the INternational VErapamil SR-trandolapril STudy (INVEST)...